SEC Form 4 · accession 0000899243-17-002765
Aimmune Therapeutics, Inc. · AIMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey H Knapp
Officer — Chief Operating Officer
Period of report
Feb 3, 2017
Accepted (ET)
Feb 3, 2017 · 6:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par value | Feb 3, 2017 | F | 2,224 | $17.89 | D | 2,776 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported sale was made pursuant to a pre-determined election to sell shares to cover tax withholding obligations in connection with the vesting of a previously reported equity award.